Search research articles
Contact Us
Filters
Showing results (191-200 of 253) with videos related to
Page
of 26
Sort By:
The Oncologist
|
May 4, 2026
Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis
Abhiraj Saxena, Marc Yorker, Nicholas A Zorko, et al.
European Urology Oncology
|
February 17, 2020
Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile
Jean Hoffman-Censits, Woonyoung Choi, Sumanta Pal, et al.
Molecular Diagnosis & Therapy
|
November 23, 2019
Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay
Pavalan Selvam, Meng-Chang Hsiao, Gregory Omerza, et al.
Urologic Oncology
|
May 21, 2014
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States
Andrea B Apolo, Joseph W Kim, Bernard H Bochner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)
Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patients
Arti Hurria, Mark T Fleming, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B Solit, S Percy Ivy, Catherine Kopil, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 19, 2016
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Hagop M Kantarjian, Bruno Lioure, Stella K Kim, et al.
Molecular Oncology
|
January 14, 2026
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
Nicolas Gordon, Peter T Gallagher, Orly I Richter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
Wm Kevin Kelly, Victoria M Richon, Owen O'Connor, et al.
Page
of 26
Search research articles
Search
Showing results (191-200 of 253) with videos related to
Sort By:
Page
of 26
The Oncologist
|
May 4, 2026
Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis
Abhiraj Saxena, Marc Yorker, Nicholas A Zorko, et al.
European Urology Oncology
|
February 17, 2020
Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile
Jean Hoffman-Censits, Woonyoung Choi, Sumanta Pal, et al.
Molecular Diagnosis & Therapy
|
November 23, 2019
Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay
Pavalan Selvam, Meng-Chang Hsiao, Gregory Omerza, et al.
Urologic Oncology
|
May 21, 2014
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States
Andrea B Apolo, Joseph W Kim, Bernard H Bochner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)
Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patients
Arti Hurria, Mark T Fleming, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B Solit, S Percy Ivy, Catherine Kopil, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 19, 2016
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Hagop M Kantarjian, Bruno Lioure, Stella K Kim, et al.
Molecular Oncology
|
January 14, 2026
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
Nicolas Gordon, Peter T Gallagher, Orly I Richter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
Wm Kevin Kelly, Victoria M Richon, Owen O'Connor, et al.
Page
of 26